A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia

Hidalgo, Manuel; Rinaldi, David; Medina, Gerardo; Griffin, Tom; Turner, J. Harvey; Hoff, Daniel D. Von

doi:10.1097/00001813-199904000-00007

Cited by 48 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A summary of these trials is provided in Table II. [52][53][54][55][56] The mechanism of action of minoxidil on the hair follicle is unclear. Perfusion studies on the hair follicle are difficult and do not necessarily correlate with skin blood flow.…”

Section: Experimental Approachesmentioning

confidence: 99%

Chemotherapy-induced alopecia

Chon

Champion²,

Geddes

et al. 2012

Journal of the American Academy of Dermatology

120

101

View full text Add to dashboard Cite

Section: Experimental Approachesmentioning

confidence: 99%

Chemotherapy-induced alopecia

Chon

Champion²,

Geddes

et al. 2012

Journal of the American Academy of Dermatology

120

101

View full text Add to dashboard Cite

“…Calcitriol has the distinction in that it is the only experimental agent that has been studied and shown to protect against CIA by paclitaxel, a major agent used to treat cancers in women (breast, ovarian) (101). Calcitriol, while it was considered the most promising agent for treating CIA (97), caused contact dermatitis and failed to protect against CIA by a combination of 5-fluorouacil, doxorubicin and cyclophosphamide in breast cancer patients (102). Parathyroid hormone (PTH)-related peptide (PTHrP) is responsible for malignancy-associated hypercalcemia, and participates in the regulation of keratinocyte proliferation and differentiation (103).…”

Section: Cell Cycle or Proliferation Modifiersmentioning

confidence: 99%

Protection Against Chemotherapy-Induced Alopecia

2006

View full text Add to dashboard Cite

Multiple classes of agents with different action mechanisms have been evaluated in animal CIA models. Most of these protective agents have activity limited to a single chemotherapeutic agent. In comparison, calcitriol and cyclosporine A have broader spectrum of activity and can prevent against CIA by multiple chemotherapeutic agents. Among the three agents that have been evaluated in humans, AS101 and Minoxidil were able to reduce the severity or shorten the duration of CIA but could not prevent CIA.

show abstract

“…For example, 1,25-dihydroxyvitamin D 3 prevented CIA in neonatal rats caused by cyclophosphamide, etoposide, or a doxorubicin-cyclophosphamide combination [22], but it was ineffective in protecting against cyclophosphamideinduced alopecia in the C57BL/6 mouse model for CIA [34]. Moreover, a topical formulation of 1,25-dihydroxyvitamin D 3 did not prevent CIA in a phase I clinical trial of breast cancer patients receiving FAC (5-FU, doxorubicin, and cyclophosphamide) [17].…”

Section: Current and Future Therapeutic Modalitiesmentioning

confidence: 99%

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Hesketh

Batchelor²,

Golant

et al. 2004

Support Care Cancer

124

View full text Add to dashboard Cite

Despite advances in the treatment of many side effects associated with chemotherapy, alopecia remains an issue that is difficult to resolve. Chemotherapy-induced alopecia (CIA) is a condition that can have profound psychosocial and quality-of-life consequences, resulting in anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being. Patients who fear CIA may sometimes select regimens with less favorable outcomes or may refuse treatment. When supporting patients with CIA, health care providers should use an individualized approach with a focus placed on the actual moment of hair loss. Education, support groups, and self-care strategies are important components of any management approach. No treatment modality for preventing CIA has been clearly shown to be effective. Recent evidence suggests that new scalp hypothermic regimens may be safe and effective. There remains a critical need for effective new approaches to this problem.

show abstract

A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia

Cited by 48 publications

References 0 publications

Chemotherapy-induced alopecia

Chemotherapy-induced alopecia

Protection Against Chemotherapy-Induced Alopecia

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Contact Info

Product

Resources

About